Cassava Sciences, Inc. SAVA 深 滬
已收盤 02-06 16:00:00 美东时间
2.03
+0.140
+7.41%
華盛通- 最 高2.065
- 今 開1.93
- 成交量 58.36万股
- 最 低 1.915
- 昨 收 1.89
- 總市值 9806.50万
- 52周最高 4.98
- 市盈率 靜 --
- 換手率 1.21%
- 52周最低 1.15
- 委 比 -61.61%
- 總股本 4830.79万
- 歷史最高 146.16
- 量 比 0.91
- 振 幅 7.94%
- 歷史最低 1.00
- 每 手 1
- 風險率 0.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cassava Sciences Announces Publication Of Article Phase 3 Randomized Clinical Trials Of Simufilam In Mild-To-Moderate Alzheimer's Disease In Upcoming Issue Of JPAD
As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ studies and
01-13 21:04
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease
Cassava Sciences announced the publication of a paper detailing results from its Phase 3 RETHINK-ALZ and REFOCUS-ALZ trials for simufilam in mild-to-moderate Alzheimer’s disease. While the studies did not meet pre-specified endpoints, exploratory analyses showed potential benefits in mild subgroups. Simufilam demonstrated slower cognitive decline in mild Alzheimer’s patients compared to placebo in REFOCUS-ALZ and pooled analyses. The company has ...
01-13 13:00
期权扫描 | 科技股普遍获看好！谷歌市值升至美股第2，多张Call单飙升；英特尔期权成交放量超2倍
科技股普遍获看好！谷歌市值升至美股第2，看涨期权占比逾7成，多张Call单大涨逾300%；英特尔股价大涨6%，期权成交放量超2倍，看涨期权占比近8成>>
01-08 17:57
Cassava Sciences to pay $31.25M to settle securities class action suit
Cassava Sciences (SAVA) announced on Tuesday that it agreed to pay $31.25M to settle a class action lawsuit pending in a Texas District Court over the company’s alleged violations of the federal secur...
2025-12-23 21:38
Cassava Announces Agreement to Settle Securities Class Action Litigation
<p>Cassava Sciences, Inc. reached a definitive agreement to settle a consolidated securities class action litigation, agreeing to pay $31.25 million. The case, originally filed in 2021, involves purchasers of the company's common stock or options between September 14, 2020, and October 12, 2023. This settlement resolves all claims against the company without admitting fault. Cassava Sciences, a biotech company developing treatments for CNS disord...
2025-12-23 13:00
Cassava Sciences drops on delay for epilepsy study
Cassava Sciences (SAVA) fell ~14% in the premarket on Friday after the company said it will be forced to delay a clinical trial for its lead candidate, simufilam, for a form of epilepsy, as it moves t...
2025-12-19 20:27
Cassava Sciences股价盘后大跌 FDA暂停该公司癫痫药物试验
Cassava Sciences股价下跌，此前该公司表示，美国食品药品管理局(FDA)已叫停其抗癫痫药物临床试验。该股周四盘后下跌15%，至2.41美元。截至周...
2025-12-19 08:38
Cassava Sciences Says Not Expected To Initiate Proof-Of-Concept Clinical Trial For Simufilam In TSC-Related Epilepsy In H1 2026 As Previously Disclosed
Following previously reported communications with the U.S. Food and Drug Administration ("FDA") regarding Cassava Sciences, Inc.'s ("Cassava" or the "Company") investigational new drug application (IND) and proposed
2025-12-19 06:12
Cassava Sciences Approves Executive Cash Bonuses for 2025
Cassava Sciences ( ($SAVA) ) has issued an announcement. On December 12, 2025, ...
2025-12-18 05:28
Cassava Sciences Submits IND Application for Simufilam
The latest announcement is out from Cassava Sciences ( ($SAVA) ). Cassava Scien...
2025-12-03 19:54
